로딩 중…
지수 로딩 중…
Daesung Microbiological Labs. Co., Ltd.
036480· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩6,220+5.07%
2026-08-04
Financials
Valuation Metrics
Daesung Microbiological Labs. Co., Ltd.'s Market Cap is ₩236B. At end of 2025 it was ₩277B. Ranked #2215 of 2,436 in KR market (top 91%), #1445 of 1,649 on KOSDAQ (top 88%), #222 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 95%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 23.64B KRW | KR#2,215/2,436 Sec#222/234 |
| Revenue | 25.87B KRW | KR#2,074/2,436 Sec#147/234 |
| Net Income | 653.7M KRW | KR#1,451/2,436 Sec#100/234 |
| Total Assets | 57.98B KRW | KR#2,106/2,436 Sec#185/234 |
| Net Assets | 35.42B KRW | KR#2,096/2,436 Sec#181/234 |
| Employees | 139 | KR#1,377/2,436 Sec#110/234 |
| Value | ||
| P/E | 36.16x | KR#1,299/2,436 Sec#82/234 |
| P/B | 0.67x | KR#1,102/2,436 Sec#57/234 |
| P/S | 0.91x | KR#1,330/2,436 Sec#75/234 |
| EV/EBITDA | 74.77x | KR#1,426/2,436 Sec#99/234 |
| FCF Yield | 4.46% | KR#901/2,436 Sec#48/234 |
| Profitability | ||
| ROE | 1.85% | KR#1,340/2,436 Sec#93/234 |
| ROA | 1.13% | KR#1,291/2,436 Sec#91/234 |
| Op. Margin | 2.06% | KR#1,356/2,436 Sec#98/234 |
| Revenue Growth | -2.29% | KR#1,568/2,436 Sec#149/234 |
| Earnings Growth | -39.45% | KR#1,151/2,436 Sec#74/234 |
| Financial Health | ||
| Debt Ratio | 63.68% | KR#216/2,436 Sec#32/234 |
| Total Debt | 19.55B KRW | KR#1,367/2,436 Sec#113/234 |
| FCF | 1.05B KRW | KR#1,142/2,436 Sec#85/234 |
| Cash | 3.34B KRW | KR#2,128/2,436 Sec#198/234 |
| Net Debt/EBITDA | 30.41x | KR#1,480/2,436 Sec#105/234 |
| Dividend | ||
| Div. Yield | 1.27% | KR#1,077/2,436 Sec#62/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -23.49% | KR#1,375/2,436 Sec#116/234 |
| 1M Return | -0.80% | KR#975/2,436 Sec#90/234 |
| From 52W High | -43.25% | KR#909/2,436 Sec#66/234 |
| 1Y MDD | -43.42% | KR#644/2,436 Sec#51/234 |
| Trading | ||
| Volume | 10,424 shares | KR#2,102/2,436 Sec#208/234 |
| Foreign Own. | 4.34% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 172 KRW | KR#1,252/2,436 Sec#88/234 |
| BPS | 9,192 KRW | KR#1,001/2,436 Sec#70/234 |
Company Info
동사는 1968년 설립되어 60여년간 동물용의약품 전문기업으로 성장하고, 2000년 코스닥시장에 상장함. 예방백신, 항생제 등 150여종 의약품을 제조·판매하며, 국내 200여개 대리점 직접판매와 조달청 납품, 6개국 수출로 내수 74%, 수출 26% 구성 보임. 신규시설 투자로 선진국 시장 진출 성장동력 확보하고, 질병 트렌드 맞춤 신제품 개발과 해외시장 공략으로 글로벌 경쟁력 강화 추구하고 있음. 대성미생물는 1966년에 설립되었으며 경기도 의왕시에 본사를 두고 있습니다.